CLNN shows severe financial deterioration with stockholders' equity nearly doubling its deficit to -$17.6M while cash reserves dropped substantially and revenue declined meaningfully.
The company's balance sheet deterioration is alarming, with stockholders' equity deficit expanding to nearly -$18M alongside a major depletion of cash reserves from $12.2M to $5.2M. The warrant expiration language changes suggest these financing instruments expired unexercised, eliminating a potential capital source when the company clearly needs funding.
CLNN experienced broad-based financial stress with revenue declining over 40% while cash reserves dropped substantially from $12.2M to $5.2M. The balance sheet weakened dramatically as the stockholders' equity deficit nearly doubled to -$17.6M and total assets contracted by one-third. Despite reduced R&D spending and modest improvements in operating losses, the company's financial position deteriorated significantly with higher interest expenses and a severely weakened capital structure.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash declined 57.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Inventory drawn down 45.6% — strong sell-through or deliberate destocking; watch for supply constraints.
Current assets declined 44.4% — monitor working capital adequacy and short-term liquidity.
Revenue declined 41.5% — significant demand weakness or market share loss warrants investigation.
Interest expense surged 38.3% — significant debt increase or rising rates materially impacting earnings.
Total assets contracted 33.7% — asset sales, write-downs, or balance sheet optimization underway.
Net income grew 33.6% — bottom-line growth signals improving overall business health.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
R&D spending cut 30.1% — could signal cost discipline or concerning reduction in innovation investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →